Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

U.S. government on the hook for COVID-19 vaccine liability

By Brian Buntz | April 14, 2021

COVID-19 vaccines NIH

[Image by Sam Moqadam on Unsplash]

There have multiple surges in malpractice claims following each wave of COVID-19 infections.

According to Victor Bornstein, CEO of Justpoint (New York City), the vast majority of those claims have targeted medical malpractice, an AI company specializing in malpractice. “The healthcare system was under a lot of stress, and more mistakes tend to happen,” Borstein said.

There hasn’t been a surge in cases related to the pandemic against pharmaceutical companies, whose COVID-19 therapies are legally shielded from lawsuits.

But the FDA’s and CDC’s joint decision to pause the use of Johnson and Johnson’s COVID-19 vaccine could lead to renewed focus on potential adverse events linked to COVID-19 vaccines.

Pharmaceutical companies themselves “cannot be sued for money damages in court” over possible injuries related to COVID-19 vaccines or therapeutics.

COVID-19 vaccines and therapeutics are, however, covered under the U.S. government’s Countermeasures Injury Compensation Program (CICP).

The program has “strict criteria,” Bornstein said.

“If someone had an issue with a COVID-19 vaccine, it’s going to be complicated for them” to be compensated, Bornstein concluded.

For one thing, payouts are limited in size.

“There’s also the question of causation,” Bornstein said. While events like anaphylaxis are relatively simple to associate with a vaccine, many side effects aren‘t. “In general medical practice, it’s easier to understand [adverse events] because you have more medical records,” he added.

But if someone who receives a vaccine develops, for instance, Bell’s palsy, it can be challenging to prove causation as the condition itself is idiopathic.

“In cases like this, the lawyers who get involved do research. It almost becomes like a scientific study,” Bornstein said. “The question becomes: ‘Are attorneys confident they will receive a payout after engaging in such extensive research?’”

But if a side effect occurs more often in the population who has received a vaccine, it is important for those experiencing the adverse events to document it. “The overall population needs to know,” Bornstein said.

“What we do know is that COVID kills,” Bornstein said. And the more people who receive the vaccine, the more functional immunity will exist across society, which will translate into fewer deaths in the long run.

Understanding the ultimate benefit-risk ratio for COVID-19 vaccines and therapeutics is a more significant undertaking, Bornstein said. “These things take time.”


Filed Under: Infectious Disease
Tagged With: adverse events, coronavirus, covid-19, COVID-19 vaccine, liability
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
Novel coronovirus
Advances in next generation vaccine development for SARS-CoV-2
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE